N@N

ARIAD to Present at the Piper Jaffray 20th Annual Healthcare Conference

^{Published on 2008-11-25 06:05:13 - Market Wire}
 

CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Piper Jaffray 20th Annual Healthcare Conference being held at The Palace Hotel in New York, New York. Harvey J. Berger, M.D., chairman and chief executive officer at ARIAD, will provide an overview of the Company and its progress in key programs on Tuesday, December 2, 2008 at 1:00 p.m. (ET).

The ARIAD presentation will be webcast live and can be accessed by visiting the investor relations section of the Company's website at [ http://www.ariad.com/investor ]. A replay will be available on the ARIAD website approximately twenty-four hours after the presentation and will be archived for two weeks.

About ARIAD

ARIAD is engaged in the discovery and development of breakthrough medicines to treat cancer by regulating cell signaling with small molecules. ARIAD is developing a comprehensive approach to patients with cancer that addresses the greatest medical need - aggressive and advanced-stage cancers for which current treatments are inadequate. ARIAD has a global partnership with Merck & Co., Inc. to develop and commercialize deforolimus, ARIAD's lead cancer product candidate, which is in Phase 3 clinical development. ARIAD's second oncology product candidate, oral AP24534, is a novel multi-targeted kinase inhibitor in Phase 1 clinical development in hematological cancers. ARIAD has an exclusive license to pioneering technology and patents related to certain NF-κB treatment methods, and the discovery and development of drugs to regulate NF-κB cell-signaling activity, which may be useful in treating certain diseases. Additional information about ARIAD can be found on the web at http://www.ariad.com.